Compare Inovio Pharmaceuticals Inc (INO) vs Plug Power Inc (PLUG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Plug Power Inc — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while Plug Power Inc trades at $2.23 (market cap $2.98B). The key difference: Plug Power Inc is far larger — about 33.4× Inovio Pharmaceuticals Inc's market cap, and Plug Power Inc is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| INO | PLUG | |
|---|---|---|
Market Cap | $89.27M | $2.98B |
Sector | Health | Industrials |
52-Week High | $2.87 | $4.14 |
52-Week Low | $1.05 | $1.40 |
Enterprise Value | $60.28M | $3.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
Plug Power (PLUG) trades at $2.14, down 0.47% on the day, reflecting ongoing investor concerns about profitability despite recent contract wins. The stock shows bearish technical signals with negative moving averages, while fundamentals reveal persistent losses with a -227.13% net income margin and negative cash flow. Recent news highlights a major 50MW Australian hydrogen project win, but operational challenges and dilution risks remain.
The outlook remains challenging with significant execution risks and cash burn, though analyst consensus suggests 36% upside to the $2.92 price target. Investment opportunity hinges on hydrogen adoption scaling faster than losses, while key risks include continued dilution, competitive pressure, and the company's ability to achieve profitability amid high debt levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Plug Power Inc
Plug Power is building an end-to-end green hydrogen ecosystem—from production, storage and delivery to energy generation. The company plans to build and operate green hydrogen highways across North America and Europe. Plug will deliver its green hydrogen solutions directly to its customers and through joint venture partners into multiple end markets—including material handling, e-mobility, power generation, and industrial applications.
Read more on PLUG →
